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Research Article
Expression of high-abundance proteins in
sera of patients with endometrial and cervical
cancers: Analysis using 2-DE with silver
staining and lectin detection methods
The expression of high-abundance serum proteins in newly diagnosed patients with endo-
metrial adenocarcinoma (EACa), squamous cell cervical carcinoma (SCCa) and cervical
adenocarcinoma (ACCa), relative to control female subjects, was analyzed by subjecting
serum samples to 2-DE followed by image analysis of the silver-stained protein profiles. The
three cohorts of cancer patients demonstrated different altered expression of serum high-
abundance proteins compared to negative control women. The expression of a1-antitrypsin,
a1-B glycoprotein, cleaved high-molecular-weight kininogen (light chain) and antithrombin
III were consistently altered in all the patients. However, clusterin was upregulated only in
the patients with EACa, while those with SCCa and ACCa were typically characterized by
the upregulated expression of zinc a-2-glycoprotein. The aberrant expression of selective
serum proteins in the various cohorts of cancer patients was validated by competitive ELISA
as well as by lectin detection. Analysis by using the champedak galactose binding lectin
further highlighted an unidentified protein that may be differently glycosylated in the sera
of the EACa patients that were studied.
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1 Introduction
Other than ovarian carcinoma, the two most common gyne-
cological malignancies that affect women worldwide are
cancers of the endometrium and the cervix. Endometrial
adenocarcinoma (EACa) is the most common type of endo-
metrial cancer while the two types of cervical cancer are
squamous cell cervical carcinoma (SCCa) and cervical ade-
nocarcinoma (ACCa), with SCCa accounting for up to 60–
80% of the cases [1].
At present, serological diagnoses of gynecological can-
cers are constrained to the analyses of CA 125, CA 19.9 and
SCC antigen tumor markers [2]. These markers are limited
in specificities and not readily detectable in early stages of the
disease. For example, CA 125 is the common tumor marker
used for diagnoses of ovarian and endometrial cancers [3, 4].
However, its presence along with CA 19.9 has also been
reported to be significantly higher in patients with ACCa
compared to SCCa patients [5]. On the other hand, SCC
antigen is adept for detection of SCCa but also serves as a
tumour marker for more advanced squamous cell tumors of
the lungs and oropharynx [6–8].
The search for new serological tumour markers is gain-
ing momentum through the use of proteomics technologies
[9, 10]. Instead of relying on single tumor markers as cur-
rently practised, proteomics approaches have unravelled se-
ries of newly detected biomarkers, which when analyzed
simultaneously may be able to discriminate different types of
cancers, their stages or monitor the progress of cancer treat-
ment towards patient’s convalescence. Considerable prote-
omics analyses have been performed on albumin and Ig
depleted serum samples. However, albumin and Igs bind to
a number of serum proteins including those that have been
clinically or experimentally used as biomarkers [11]. Thus,
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the removal of albumin and Ig’s may indirectly contribute to
the differential expression of proteins that was detected.
Previous studies using whole unfractionated serum
samples of rats and humans have demonstrated that even
high-abundance proteins could be the markers for disease
states [12–15]. By using 2-DE and image analysis, we have
reported the aberrant expression of high-abundance acute-
phase serum proteins in patients with cancers of the breast
(breast carcinoma; BrCa) and nasopharynx (nasopharyngeal
carcinoma; NPCa). While patients with BrCa demonstrated
different altered expression of serum a1-antichymotrypsin
(ACT), clusterin (CLU) and complement factor B [13], cer-
uloplasmin was the sole high-abundance protein that was
upregulated in the sera of NPCa patients [14]. However, the
question of whether the altered patterns of expression of the
serum proteins is truly unique for the respective cancers
could only be resolved if similar proteomics analyses were
broadened to patients with other types of cancer.
In the present study, analysis of the expression of high-
abundance serum proteins has been extended to newly
diagnosed patients afflicted with EACa, SCCa and ACCa. In
addition, we have also generated 2-DE profiles of O-glycosy-
lated serum proteins of the patients by using the champedak
galactose binding (CGB) lectin probe and compared them
with that obtained from normal negative control women.
2 Materials and methods
2.1 Serum samples
Serum samples were obtained from patients newly con-
firmed with gynecological malignancies at the Gynecology
Clinic, University of Malaya Medical Center, Kuala Lumpur,
prior to treatment or surgery. The patients (EACa (n = 12),
SCCa (n = 10) and ACCa (n = 7)), with ages ranging from 35
to 65 years, were histopathologically confirmed for stage 1A
or 1B carcinoma. Control sera (n = 13) were obtained from
normal healthy women volunteers of the same range of age.
Samples were obtained with patient’s consent and approval
granted by the Ethical Committee (Institutional Review
Board) of the Medical Centre in accordance to the ICH GCP
guideline and the declaration of Helsinki. All the samples
were subjected to similar treatment and kept in aliquots of
100 mL at 2807C.
2.2 2-DE
2-DE was performed as previously reported [13]. Briefly, 7 mL
of unfractionated whole human serum sample (450 mg of
protein) was subjected to IEF in 11 cm rehydrated precast
Immobiline Drystrips at pH 4–7 (GE Healthcare Bio-
Sciences, Uppsala, Sweden). For the second dimension,
focused samples in the strips were subjected to electropho-
resis using 8–18% gradient polyacrylamide gel in the pres-
ence of SDS. All the samples were analyzed in duplicate.
2.3 Gel staining
The 2-DE gels were developed by silver staining as described
by Heukeshoven and Dernick [16]. For mass spectrometric
analysis, gels were stained using Coomassie colloidal stain.
The Coomassie stain was prepared by dissolving 0.1% w/v
Phast Blue R350 (GE Healthcare BioSciences) in 10% acetic
acid solution that was preheated to 907C. Gels were stained
on a rocking platform for a period of 30 min followed by
destaining with 10% acetic acid solution.
2.4 MS
Protein spots were initially identified by comparing highly
resolved serum protein profiles with the Swiss ExPASy
standard plasma protein reference [17]. 2-DE gel plugs of
spots of proteins of interest were sent for MS analysis using
MALDI-TOF at the Biomolecular Research Facility, Uni-
versity of Newcastle, Australia. Samples that were not posi-
tively identified were then subjected to MS/MS analysis at
the Australian Proteomic Analysis Facility (APAF), Mac-
quarie University, Sydney, Australia. Gel plugs were kept in
fresh eppendorf tubes containing small volumes of Milli-Q
water to ensure that they remained hydrated prior to analy-
sis.
2.5 Database searches
Identities of protein spots of interest were initially deter-
mined by the Biomolecular Research Facility, University of
Newcastle, Australia. The identities were reconfirmed using
MASCOT program (http://www.matrixscience.com) by sub-
mitting the mass list data to the peptide mass fingerprint
search. The following parameters were used in the searches:
trypsin digest (allowing one missed cleavage); species, Homo
sapiens; mass value, monoisotopic; peptide mass tolerance,
60.1 Da; peptide charge state, 11 and against the NCBInr
database. The same parameters were used in the MASCOT
ions search for the MS/MS data, except peptide mass and
fragment mass tolerance were set at 6300 ppm and
60.6 Da, respectively.
2.6 Western blotting and lectin detection
The 2-DE gels were transferred electrophoretically onto an
NC membrane (0.45 mm) using a NovaBlot Kit of the Multi-
phor II Electrophoresis System (GE Healthcare Bio-
Sciences). Blotting was performed at 0.8 mA/cm2 for 2 h.
Detection of transferred O-glycosylated serum proteins was
performed using CGB lectin which was conjugated to
horseradish peroxidase (HRP). The lectin was chosen based
on its specific interaction with O-glycans of glycoproteins
[18]. Purity and specificity of the lectin were confirmed using
previously described biochemical and immunochemical
analyses [18–20]. Blots were developed using 3,30-diamino-
benzidine (BioRad Laboratories, Hercules, CA, USA). Reac-
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tion was stopped by washing the membrane twice with dis-
tilled water. The blots were air dried prior to densitometric
scanning and image analysis.
2.7 Image analysis
The silver-stained gels and lectin blots were scanned using a
densitometer (Imaging Densitometer GS690, BioRad
Laboratories). Protein spots were analysed in terms of vol-
ume performed using the Image Master 2D-Platinum soft-
ware, version 5.0 (GE Healthcare BioSciences). The back-
ground was subtracted and analysis was restricted to 12
clusters of protein spots with Mr  30 000, i.e. a1-antitrypsin
(AAT), a2-HS glycoprotein (AHS), a1-B glycoprotein (ABG),
haptoglobin b-chain (HAP), ACT, CLU, anti-thrombin III
(ATR), leucine-rich glycoprotein (LRG), cleaved high-molec-
ular-weight kininogen light chain (KNG) and zinc a-2-glyco-
protein (ZAG) for the 2-DE protein profiles that were gener-
ated by silver staining. Analysis of the 2-DE protein profiles
developed by interaction with lectin was performed on ACT,
AHS, LRG, hemopexin (HPX), KNG and unidentified pro-
teins LDP1, LDP2 and LDP3. Albumin, serum polypeptides
having idiotypic and/or allotypic variations (such as the
heavy and light chains of all the isotypes of Igs and the a
chains of HAP) and the low Mr protein spots, the majority of
which were not well resolved under the settings of our
experiments, were not assessed. The percentage volume
contribution refers to the volume percentage of a protein
taken against the total spot volume of all the proteins
including the unresolved peptides in each gel.
2.8 Competitive ELISA
Competitive ELISA was performed as previously described
[13]. The levels of AAT, ATR, CLU and ABG in serum sam-
ples were reflected by their ability to inhibit the specific
binding of antisera to the respective serum proteins. Primary
antisera against AAT and ATR were obtained from the Bind-
ing Site (Birmingham, UK) while those against CLU and
ABG were purchased from Upstate Biotechnology (Lake
Placid, USA) and Aviva Systems Biology (San Diego, USA),
respectively. Assay was not performed for LRG and ZAG as
antisera to the serum proteins were not available commer-
cially. HRP-conjugated secondary antisera comprising don-
key anti-sheep IgG, goat anti-mouse IgG and goat anti-rabbit
IgG, were obtained from the Binding Site, Sigma-Aldrich (St.
Louis, USA) and BioRad Laboratories, respectively. Enzyme
activity was revealed by the addition of 3,30,5,50-tetra-
methylbenzidine (Pierce, Rockford, IL, USA). The amount of
specific proteins in the test sera is proportional to the per-
centage inhibition of substrate hydrolysis.
2.9 Statistical analysis
All the values are presented as mean 6 SD. The Student’s
t-test was used to analyze the significance of differences be-
tween normal subjects and patients. A p-value of less than
0.05 was considered significant.
3 Results
When unfractionated whole serum samples from newly
diagnosed patients with EACa (n = 12), SCCa (n = 10) and
ACCa (n = 7) as well as normal healthy women (n = 13) were
subjected to 2-DE and silver staining, high-resolution serum
protein profiles were obtained (Fig. 1). Among the high-
abundance proteins that were well resolved in the various
protein profiles were AAT, ABG, ACT, AHS, ATR, CLU,
HAP, KNG, LRG and ZAG.
The identities of AAT, ABG, ACT, AHS and HAP were
confirmed by subjecting their spot clusters to in gel trypsin
digestion and MS, as previously reported [13]. In cases of the
spot clusters of ATR, CLU, LRG and ZNG, initial identifica-
tion was made through comparison with the Swiss ExPASy
standard plasma protein reference map [17] and this was
further confirmed by subjecting the protein spot clusters to
MALDI-MS analysis and database search (Table 1). KNG was
identified using 1-D LC-MS/MS with nine sequences of
peptides correlating to the protein.
Volume analysis of ten selective well-resolved spot clus-
ters in the 2-DE profiles of patients, compared to that of
control women, demonstrated different altered expression of
serum high-abundance proteins in the various cohorts of
cancer patients that were studied (Fig. 2). The upregulated
expression of ABG, ATR, CLU and LRG and downregulated
expression of AAT and KNG were significantly detected in
the profiles of the EACa patients. The expression of serum
high-abundance proteins was similar in the two cohorts of
patients with SCCa and ACCa. In both these cohorts of cer-
vical cancer patients, significant upregulated expression was
detected for ABG, ATR and ZAG, while the expression of
AAT and KNG was significantly lower. The expression of
AHS, ACT and HAP was not significantly different between
patients and control women.
For confirmation of the aberrantly expressed identified
proteins in sera of the respective cancer patients, competitive
ELISA was carried out by using antisera to the selective
serum proteins. Table 2 summarizes of the results of the
competitive ELISA as compared to the data obtained from
analysis by 2-DE. Higher levels of ABG and ATR and lower
levels of AAT were significantly detected in sera of all the
patients (EACa (n = 12), SCCa (n = 10) and ACCa (n = 7))
compared to normal controls (n = 13). The expression of
CLU was only enhanced in the patients with EACa but not
significantly different for patients with SCCa and ACCa.
The application of lectin to probe selective glycosylated
polypeptides which were resolved by 2-DE allows one to
validate the data obtained by silver staining as well as to
screen for the possible presence of structural aberration in
the oligosaccharide moieties of the serum glycoproteins.
When 2-DE separated sera of patients and negative control
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Figure 1. Typical serum protein profiles of negative control women and patients with EACa, SCCa and ACCa. Unfractionated whole serum
samples of normal healthy control women were subjected to 2-DE and silver staining. (a) Typical serum protein profile of a healthy control
woman. Clusters of protein spots clearly resolved include AAT, ABG, ACT, AHS, ATR, CLU, HAP, KNG, LRG and ZAG. (b–d) Typical repre-
sentative unfractionated serum protein profiles of the EACa, SCCa and ACCa patients, respectively. The aberrantly expressed proteins are
marked in brackets for panels (b–d). For all the panels, the acidic sides of the 2-DE gels are to the left and Mr declines from the top.
women were exposed to enzyme-conjugated champedak
galactose binding (CGB) lectin, different profiles comprising
only O-glycosylated peptides were obtained (Fig. 3). The
spots of HPX appeared to be well resolved in the profiles with
the absence of the albumin streak that usually appeared
using the silver staining method. The spots of KNG, an O-
glycosylated polypeptide, were further validated as they were
recognized by the lectin. Three additional unidentified pro-
tein spot clusters that were not detected in the silver-stained
profiles, termed LDP1, LDP2 and LDP3, were also observed.
Comparable results were generally observed for the 2-DE O-
glycosylated peptide profiles of the two cohorts of patients
with cervical cancer and control subjects. However, EACa
patients were notably different for their intense expression of
LDP1.
Subjecting the 2-DE lectin-detected serum protein pro-
files to densitometry analysis confirmed the lowered expres-
sion of KNG in all cohorts of cancer patients and the signifi-
cant enhanced expression of LDP1 in patients with EACa
compared to negative control women (Fig. 4). The image
analysis also detected significant reduced expression of HPX
selectively in the same cohort of cancer patients. Like that
observed in the silver-stained 2-DE analysis, the levels of
AHS and ACT were not significantly different between
patients and negative control women. However, the levels of
LRG were not significantly different between all patients and
negative control women, although our data obtained by silver
staining demonstrate significant difference of the LRG
expression in patients with EACa. The expression of LDP3
was significantly reduced in all three cohorts of cancer
patients compared to the controls.
4 Discussion
The present study, performed by subjecting serum samples
to 2-DE followed by silver staining and image analysis,
demonstrated different altered levels of several high-abun-
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Table 1. Mass spectrometric identification of spot clusters from serum protein profiles
Spot IDa) Accession
No.b)
Mr (kDa)/calculated pI Number of peaks
matched (number
of peaks searched)
MASCOT
score
Sequence
percent
coverage (%)
ATR gi)179161 53.05/6.32 12(24) 79 33
CLU gi)338305 37.00/5.74 7(13) 60 26
LRG gi)72059 34.55/5.66 8(16) 69 29
ZAG gi)7246026 31.86/5.70 14(22) 135 54
KNGc) gi)125507 71.95/6.34 9d) 434 19
a) Spot ID are as in Fig. 1. Mr: nominal mass.
b) Accession numbers are from the MASCOT database (www.matrixscience.com).
c) Identified by LC-MS/MS analysis.
d) Number of peptides matched.
Figure 2. Mean percentage of volume contribution of 2-DE-resolved serum proteins. Volumes of protein spots were analyzed using the
Image Master 2D-Platinum software, version 5.0. Analysis was restricted to ten clusters of protein spots including AAT, ABG, ACT, AHS,
ATR, CLU, HAP, KNG, LRG and ZAG. Asterisks (*) denote significantly different values.
Table 2. Relative expression of serum proteins analyzed by 2-DE and ELISA
Serum
proteins
Analysis by 2-DE Analysis by ELISA
Fold changes relative to that of control Fold changes relative to that of control
EACa patients SCCa patients ACCa patients EACa patients SCCa patients ACCa patients
AAT 20.6 (p = 0.005) 20.7 (p = 0.005) 20.5 (p = 0.0003) 20.4 (p = 0.0001) 20.5 (p = 0.006) 20.3 (p = 0.0008)
ABG 12.2 (p = 0.0001) 13.1 (p = 0.0001) 12.2 (p = 0.002) 11.6 (p = 0.0001) 11.6 (p = 0.001) 11.4 (p = 0.003)
ACT n.s. n.s. n.s. n.d. n.d. n.d.
AHS n.s. n.s. n.s. n.d. n.d. n.d.
ATR 110.3 (p = 0.0001) 115.6 (p = 0.0001) 14.1 (p = 0.01) 12.3 (p = 0.0001) 12.2 (p = 0.0001) 12.2 (p = 0.0001)
CLU 13.3 (p = 0.002) n.s. n.s. 11.0 (p = 0.005) n.s. n.s.
HAP n.s. n.s. n.s. n.d. n.d. n.d.
KNG 20.5 (p = 0.0001) 20.01 (p = 0.0001) 20.3 (p = 0.002) n.d. n.d. n.d.
LRG 110.9 (p = 0.01) n.s. n.s. n.d. n.d. n.d.
ZAG n.s. 12.6 (p = 0.0003) 13.5 (p = 0.0001) n.d. n.d. n.d.
1, Increase in expression; 2, decrease in expression; n.s., not significant and n.d., not determined.
The Student’s t-test was used to analyze the significance of differences between normal subjects and patients. A p-value of less than 0.05
was considered significant.
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Figure 3. Analysis of O-glycosylated serum proteins by detection with CGB-lectin. Unfractionated serum samples of normal female con-
trols (a), patients with EACa (b), patients with SCCa (c) and patients with ACCa (d), were subjected to 2-DE and lectin blotting. O-Glycosy-
lated serum protein spots resolved included IgA, ACT, AHS, HPX, KNG and LRG and three unidentified glycoproteins termed, LDP1, LDP2
and LDP3. The aberrantly expressed proteins are marked in parentheses.
dance proteins in the respective cohorts of patients with
EACa, SCCa and ACCa, relative to negative control women.
The upregulated expression of ABG and ATR and down-
regulated expression of AAT and KNG were consistently
observed in all the patients. However, CLU and LRG were
upregulated only in the EACa patients, while patients with
SCCa and ACCa were typically characterized by the upregu-
lated expression of ZAG.
By using ELISA, the altered levels of ABG, ATR, AAT
and CLU in the respective cohorts of the cancer patients
were confirmed although the magnitude of fold differences
were much lower compared to the 2-DE analysis. This is
indicative of the higher sensitivity of 2-DE compared to
ELISA when used to differentiate the levels of serum pro-
teins.
Taken together, the altered patterns of expression of high-
abundance proteins detected for EACa, SCCa and ACCa were
different when compared to our previously reported protein
expression profiles of patients with BrCa and NPCa [13, 14],
although the upregulated expression of CLU and down-
regulated expression of AAT have also been observed for the
BrCa patients.
Probable reasons for the altered expression of CLU and
AAT in cancer patients have been discussed in our pre-
vious report on BrCa [13]. The association of ABG and
LRG, secretory proteins of unknown function [21, 22], with
cancer has not been reported. Nevertheless, heavily glyco-
sylated membrane proteins, with regions containing leu-
cine-rich repeats similar to LRG, have been shown to be
overexpressed in premalignant mammary epithelial cells
[23] and BrCa tissues [24].
ATR is an important serine protease inhibitor in the
plasma that is involved in the regulation of the blood coagu-
lation cascade [25]. Differential levels of serum ATR in
patients with EACa, SCCa and ACCa have not been pre-
viously reported although the increased levels of ATR–
thrombin complex have been demonstrated in the plasma of
lung cancer patients [26] as well as patients with the various
gynecological cancers [27]. Among the latter, the highest
levels of ATR–thrombin complex were detected in patients
with ovarian carcinoma, followed by cervical cancer patients
and endometrial cancer patients, respectively [27]. Increased
ATR detected in the sera of EACa, SCCa and ACCa patients
in the present study may or may not have been part of such
complex. However, this could not be verified using the
approach in the present study as thrombin, which consists of
6 and 31 kDa subunits, could not be detected within the
resolved range of our 2-DE.
In the case of ZAG, previous reported studies have also
demonstrated overexpression of the protein in sera of
patients with prostate carcinoma [28] and BrCa [29]. Al-
though we have not detected the expression of ZAG in our
previous studies on BrCa patients [13], higher expression of
the protein was clearly observed in all 2-DE serum protein
profiles of patients with SCCa and ACCa in the present study.
To the best of our knowledge, there had been no previous
report on ZAG expression in patients with gynecological
cancer. ZAG, named due to its tendency to precipitate zinc
© 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.electrophoresis-journal.com
Electrophoresis 2007, 28, 0000–0000 Proteomics and 2-DE 7
Figure 4. Mean percentage of volume contribution of CGB-lectin detected serum O-glycosylated proteins. Volumes of O-glycosylated
protein spots were analyzed using Image Master 2D-Platinum software, version 5.0. Analyses were restricted to eight clusters of protein
spots including ACT, AHS, HPX, KNG and LRG and unidentified glycoproteins, LDP1, LDP2 and LDP3. Asterisks (*) denote significantly
different values.
salts and also known as a-2 glycoprotein, is secreted by a
variety of normal epithelia [30]. It stimulates lipolysis of adi-
pocytes [31], and thus, may be involved in the development of
cancer cachexia.
The use of enzyme-conjugated lectin to detect 2-DE
separated O-glycosylated proteins further confirmed compa-
rable expression of AHS and ACT between patients and
negative control women as well as the patients’ down-
regulated expression of KNG. KNG, an O-glycosylated serum
polypeptide, is the light chain component of cleaved high-
molecular-weight kininogen (HKa). HKa is known for its
antiangiogenic properties as well as its inhibitory action on
the proliferation of endothelial cells [32]. Our data suggest
that the sera of patients with EACa, SCCa and ACCa were
physiologically depleted of KNG. The disappearance of KNG
from patients’ sera was probably due to involvement of HKa
in mechanisms to counter cancer-related angiogenesis and
cell proliferation. A similar reduction in KNG expression was
also observed in sera of patients with breast cancer (pre-
viously reported as unidentified protein, PR3 [13]), while
reduced levels of high-molecular-weight kininogen have
been detected in the plasma of patients with gastrointestinal
cancer [33].
In addition to its use in validating the 2-DE data, the lec-
tin approach provided an extra avenue to determine expres-
sion of additional high-abundance serum proteins that were
either not detected or not well resolved using the silver
staining method. Reduced levels of LDP3 in all three cohorts
of patients and different altered levels of LDP1 and HPX
specifically in patients with EACa were further shown.
However, the expression of LRG was not significantly differ-
ent between all cohorts of patients and negative control
women. This is contrary to the earlier data that demonstrated
significantly higher expression of LRG in EACa patients
using silver staining. The different results may be resolved
by increasing the sampling size of patients and controls in
both experiments.
The marked difference in the intensities of LDP1 detected
between EACa patients and control women using enzyme-
conjugated CGB lectin is perhaps more intriguing. Since this
disparity was not detected in the earlier studies by silver
staining, there is a strong possibility that the protein may be
differently glycosylated. This is not exactly unexpected since
the CGB lectin binds to the O-linked oligosaccharides [18]
which contain core Galb1-3GalNAc structure. The di-
saccharide moiety, also known as the Thomsen–Friedenreich
(TF) antigen, is one of the carbohydrate tumor antigens of the
cell membrane [34]. It is cryptically present in O-glycans of a
variety of membrane glycoproteins and becomes exposed
during transition tomalignancy [35]. In the present study, this
is reflected in the secretory serum protein, LDP1, which
demonstrated weak interaction with the CGB lectin in nega-
tive control women but appeared to react strongly with the
lectin in patients with EACa. Because of the difference in car-
bohydrate structures between LDP1 in EACa patients com-
pared to control women, the serum glycoprotein is a likely
candidate as a serological marker for diagnosis of the cancer.
However, the identity of LDP1 (aswell as LDP2 andLDP3)was
not possibly determined using the present methods of MS.
Visual comparisonof the 2-DE serumproteinprofileswith the
Swiss ExPASy profiles also failed to detect any precise match
with the annotated plasma proteins.
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